PVCT
Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes, led by rose bengal sodium (RBS). Provectus' proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the investigational drug and preclinical formulations of our drug development programs. Pharmaceutical-grade RBS displays different therapeutic effects at varying concentrations, and can be formulated for delivery by several routes of administration. RBS targets disease in a bifunctional manner. Direct contact may lead to cell death or repair depending on the disease treated and the RBS concentration utilized. Multivariate immune signaling, activation, and response may follow that manifests as stimulatory, inhibitory, or both. Provectus is the first entity to advance an RBS formulation into clinical trials, and the first and only entity to date to consistently make pharmaceutical-grade RBS at a purity of nearly 100%. Our drug pipeline includes clinical programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, wound healing, and animal health; and preclinical in vitro programs in infectious diseases and tissue regeneration. Information about our clinical trials can be found at www.clinicaltrials.gov. For information about Provectus, please visit www.provectusbio.com